Stable anandamide analog that is a selective agonist for the CB1 receptor (Ki values are 20 and 815 nM for CB1 and CB2 receptors respectively). Also displays agonist activity at vanilloid receptors.
Water Soluble Emulsion also available.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in ethanol (supplied pre-dissolved in anhydrous ethanol, 5mg/ml)|
Preparing Stock Solutions
The following data is based on the product molecular weight 361.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.77 mL||13.83 mL||27.66 mL|
|5 mM||0.55 mL||2.77 mL||5.53 mL|
|10 mM||0.28 mL||1.38 mL||2.77 mL|
|50 mM||0.06 mL||0.28 mL||0.55 mL|
References are publications that support the products' biological activity.
Abadji et al (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J.Med.Chem. 37 1889 PMID: 8021930
Carriero et al (1998) A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl.) 137 147 PMID: 9630001
Khanolkar et al (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J.Med.Chem. 39 4515 PMID: 8893848
Zygmunt et al (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 452 PMID: 10440374
If you know of a relevant reference for (R)-(+)-Methanandamide, please let us know.
View Related Products by Product Action
Keywords: (R)-(+)-Methanandamide, supplier, Potent, selective, CB1, agonists, Cannabinoids, Receptors, cb1r, CB1, Receptors, CB1, Receptors, Tocris Bioscience
6 Citations for (R)-(+)-Methanandamide
Citations are publications that use Tocris products. Selected citations for (R)-(+)-Methanandamide include:
Cenni et al (2006) Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur J Neurosci 24 1633 PMID: 17004927
Grace et al (2014) Identification of a pharmacological target for genioglossus reactivation throughout sleep. Nat Chem Biol 37 41 PMID: 24470694
Korossy-Mruk et al (2013) Neonatal DSP-4 treatment modifies antinociceptive effects of the CB1 receptor agonist methanandamide in adult rats. Neurotox Res 23 39 PMID: 22488162
Mendiguren and Pineda (2009) Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br J Pharmacol 158 1579 PMID: 19845674
Carney et al (2009) Cannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cells. J Neuroimmune Pharmacol 4 338 PMID: 19365734
Justinova et al (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 33 2870 PMID: 18305459
Do you know of a great paper that uses (R)-(+)-Methanandamide from Tocris? If so please let us know.
Reviews for (R)-(+)-Methanandamide
There are currently no reviews for this product. Be the first to review (R)-(+)-Methanandamide and earn rewards!
Have you used (R)-(+)-Methanandamide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.